SI-BONE, Inc.
SIBNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, SI-BONE, Inc. (SIBN) is listed under Medical Devices. With a market capitalization of $952.6M, it sits in small-cap territory. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
Market Cap
$952.6M
Beta
0.66
P/E (TTM)
—
P/E (Fwd)
-64.93
EPS (TTM)
$-0.34
EPS (Fwd)
$-0.33
ROE
-8.3%
ROA
-4.6%
Cash
$145.9M
Total Debt
$42.8M
Free CF
-$861,875
52W Change
37.2%
Annual Financials
Cash vs Debt
Where SIBN stands vs its 150-day and 200-day moving averages
As of the October 8, 2026 close, SIBN finished 19.30% above its 150-day moving average ($16.01) and 16.89% above its 200-day moving average ($16.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SIBN overbought or oversold?
At the October 8, 2026 close, SIBN's RSI(14) was 60.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SI-BONE, Inc. holds $145.9M in cash against $42.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$862K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -8.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $90.2M (2021) to $200.9M (2025), reflecting a 123% increase over the period.
SIBN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SI-BONE, Inc.'s trajectory.